RAS mutations in patients following cytotoxic therapy for lymphoma.

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Back to search

Article

RAS mutations in patients following cytotoxic therapy for lymphoma.

Oncogene - 1 Mar 1990

Carter G, Hughes D C, Clark R E, McCormick F, Jacobs A, Whittaker J A, Padua R A

Abstract excerpt

The occurrence of Myelodysplastic Syndrome (MDS) and Acute Myeloblastic Leukaemia (AML) following cytotoxic therapy for neoplastic disease is well recognised. RAS mutations are common in patients with MDS and AML. To determine whether these lesions are found as early markers of secondary disease, we have studied the incidence of RAS mutations in the peripheral blood of 70 patients in complete remission from...

Topics

Animals
Antineoplastic Agents
Cell Transformation, Neoplastic
Cells, Cultured
Combined Modality Therapy
DNA, Neoplasm
Genes, ras
Hodgkin Disease
Humans
Lymphoma
Lymphoma, Non-Hodgkin

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Mice

Mice, Inbred Strains

Mice, Nude

Mutation

Nucleic Acid Hybridization

Polymerase Chain Reaction

Transfection

Source

Open in PubMed

Identifiers

PMID: 2179819

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 29 Aug 2026. Prepared record publication-2179819-2026-08-29.1. Manifest publication-graph-cohort-2026-08-29.1.

Source receipt: PubMed via Helena Literature Corpus, retrieved 29 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 11 closest

RAS mutations in patients following cytotoxic therapy for lymphoma.PMID 2179819Read ↗

Genetic lesions in preleukemia.Semantic proximity Read ↗

Mutations of the Kirsten-ras proto-oncogene in human preleukaemia.Semantic proximity Read ↗

Prognostic importance of mutations in the ras proto-oncogenes in de novo acute myeloid leukemia.Semantic proximity Read ↗

Mutations in the ras proto-oncogenes in patients with myelodysplastic syndromes.Semantic proximity Read ↗

Longitudinal analysis of point mutations of the N-ras proto-oncogene in patients with myelodysplasia using archived blood smears.Semantic proximity Read ↗

In vivo somatic mutation in the lymphocytes of Hodgkin's disease patients.Semantic proximity Read ↗

A screen for RAS mutations in individuals at risk of secondary leukaemia due to occupational exposure to petrochemicals.Semantic proximity Read ↗

A point mutation at codon 13 of the N-ras oncogene in myelodysplastic syndrome.Semantic proximity Read ↗

Analysis of ras gene mutations in childhood myeloid leukaemia.Semantic proximity Read ↗

Point mutations of the N‐<i>ras</i> gene in the blood plasma DNA of patients with myelodysplastic syndrome or acute myelogenous leukaemiaSemantic proximity Read ↗

N-RAS mutations and susceptibility to lymphokine-activated killer (LAK) cells in human melanoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.